Please replace the paragraph beginning at page 32, line 21 with the following rewritten paragraph:

--The PC3 cell line was maintained in RPMI supplemented with 10% fetal calf serum and antibiotics. Cells were suspended in 0.12% soft agar in complete medium and plated (2,000 cells per well) in different drug concentrations onto a 0.4% agarose underlayer in 24-well plates. Plating cells on agarose underlayers supports the proliferation only of the transformed cells, ensuring that the growth signal stems from the malignant component of the tumor.--

Please replace the paragraph beginning at page 37, line 24 with the following rewritten paragraph:

--Cells were treated with test compounds and CFTR immunoprecipitated as described in Bradbury et al., *Am. J. Physiol.* 276, L659 - 668 (1999). Briefly, treated cells were lysed in buffer containing 1% TRITON X-100 and various protease inhibitors. Soluble material was immunoprecipitated using both R domain and C-terminal monoclonal antibodies. Immunoprecipitated CFTR was then subject to *in vitro* phosphorylation using camp-dependent PKA catalytic subunit and [γ-32P]ATP, followed by resolution on SDS-PAGE gels. After fixation, the gels were dried and processed for autoradiography and phosphor image analysis. Quantitation of B and C bands was performed on a BioRad personal fix image analysis station.--

In the claims:

Please amend claims 1, 20, 21, 22 and 43 as follows:

--1. ~~A compound~~ of formula (I):



(I)

wherein

A is a cyclic moiety selected from the group consisting of C_{3-14} cycloalkyl, 3-14 membered heterocycloalkyl, C_{4-14} cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, and heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl;

each of X^1 and X^2, independently, is O or S;

each of Y^1 and Y^2, independently, is $-CH_2-$, -O-, -S-, $-N(R^a)-$, $-N(R^a)-C(O)-O-$, $-O-C(O)-N(R^a)-$, $-N(R^a)-C(O)-N(R^b)-$, $-O-C(O)-O-$, or a bond; each of R^a and R^b, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

L is a straight C_{3-12} hydrocarbon chain optionally containing at least one double bond, at least one triple bond, or at least one double bond and one triple bond; said hydrocarbon chain being optionally substituted with C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, hydroxyl, halo, amino, nitro, cyano, C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkyloxycarbonyl, C_{1-4} alkylcarbonyl, or formyl; and further being optionally interrupted by -O-, $-N(R^c)-$, $-N(R^c)-C(O)-O-$, $-O-C(O)-N(R^c)-$, $-N(R^c)-C(O)-N(R^d)-$, or $-O-C(O)-O-$; each of R^c and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; that when L contains three double bonds, said hydrocarbon chain is substituted with C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, hydroxyl, halo, amino, nitro, cyano, C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkyloxycarbonyl, C_{1-4} alkylcarbonyl, or formyl; and further provided that when L contains less than 6 carbon atoms in the hydrocarbon chain and A is C_{1-4} alkyl phenyl or unsubstituted phenyl, Y^1 is not a bond;

or a salt thereof.--

--20. The compound of claim 1, said compound being 4-chloro-5-phenyl-2,4-pentadienoic acid, 5-(4-dimethylaminophenyl)-2,4-pentadienoic acid, 5-(2-furyl)-2,4-

pentadienoic acid, 5-phenyl-2-en-4-yn-pentanoic acid, or 8-phenyl-3,5,7-octatrienoic acid.--

--21. The compound of claim 1, said compound being 8-phenyl-3,5,7-octatrienoic acid.--

--22. A compound of formula (I):



(I)

wherein

A is a cyclic moiety selected from the group consisting of aryl and heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, or amino;

each of X^1 and X^2, independently, is O or S;

each of Y^1 and Y^2, independently, is $-CH_2-$, -O-, -S-, $-N(R^a)-$, $-N(R^a)-C(O)-O-$, $-O-C(O)-N(R^a)-$, $-N(R^a)-C(O)-N(R^b)-$, $-O-C(O)-O-$, or a bond; each of R^a and R^b, independently, being hydrogen, alkyl, hydroxylalkyl, or haloalkyl;

L is a straight C_{3-12} hydrocarbon chain optionally containing at least one double bond, at least one triple bond, or at least one double bond and one triple bond; said hydrocarbon chain being optionally substituted with C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, or amino, and further optionally interrupted by -O- or $-N(R^c)-$, where R^c is hydrogen, alkyl, hydroxylalkyl, or haloalkyl; provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; that when L contains three double bonds, said hydrocarbon chain is substituted with C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, hydroxyl, halo, amino, nitro, cyano, C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkyloxycarbonyl, C_{1-4} alkylcarbonyl, or formyl; and further provided that when L contains less than 6 carbon atoms in the hydrocarbon chain and A is C_{1-4} alkyl phenyl or unsubstituted phenyl, Y^1 is not a bond;

or a salt thereof.--

--43. The compound of claim 40, wherein L is an unsaturated C_{4-8} hydrocarbon chain containing at least one double bond in trans configuration, said unsaturated hydrocarbon chain being optionally substituted with C_{1-2} alkyl, C_{1-2} alkoxy, hydroxyl, $-NH_2$, $-NH(C_{1-2}$ alkyl), or $-N(C_{1-2}$ alkyl$)_2$.--